Abstract

Drug and chemical development along with safety tests rely on the use of numerous clinical models. This is a lengthy process where animal testing is used as a standard for pre-clinical trials. However, these models often fail to represent human physiopathology. This may lead to poor correlation with results from later human clinical trials. Organ-on-a-Chip (OOAC) systems are engineered microfluidic systems, which recapitulate the physiochemical environment of a specific organ by emulating the perfusion and shear stress cellular tissue undergoes in vivo and could replace current animal models. The success of culturing cells and cell-derived tissues within these systems is dependent on the scaffold chosen; hence, scaffolds are critical for the success of OOACs in research. A literature review was conducted looking at current OOAC systems to assess the advantages and disadvantages of different materials and manufacturing techniques used for scaffold production; and the alternatives that could be tailored from the macro tissue engineering research field.

Highlights

  • IntroductionResearch and development in the pharmaceutical and chemical industries have encountered barriers since their conception with regards to the development and selection of appropriate pre-clinical test models [1]

  • This paper aims to provide a summary of scaffold requirements, review different materials and manufacturing techniques that can be used to produce the optimal scaffold according to the OOAC specifications

  • We reviewed the different materials and manufacturing techniques that could be used to produce scaffolds for the OOAC research field

Read more

Summary

Introduction

Research and development in the pharmaceutical and chemical industries have encountered barriers since their conception with regards to the development and selection of appropriate pre-clinical test models [1]. Pre-clinical testing relies on animals or animalderived models, which are costly, have significant ethical implications and are not accurate representations of human physiopathology [2]. Significant progress has been made in developing and validating robust/reliable alternative test systems. This has been driven by an increasing acceptance of regulators and industry to commit to the three Rs of animal usage in research (replacement, reduction and refinement) [3]

Objectives
Findings
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call